阿尔茨海默病:不断发展的治疗方法,科学进步和关键挑战
Sai Yasasvi K1, Amit Kumar Goswami1, Manasi Ramu Prasad1,2
1School of Pharmacy, Gandhi Institute of Technology and Management (GITAM), Deemed to be University, Gandhi Nagar, Rushikonda, Visakhapatnam, Andhra Pradesh 530045, India.
Journal of medicinal chemistry
|February 13, 2026
概括
阿尔茨海默氏病涉及粉样β (Aβ) 聚合和问题. 针对Aβ聚合提供治疗潜力,但面临挑战,需要多方面的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是粉样β (Aβ) 聚合,病理和神经毒性.
- Aβ聚合是关键的病理特征,但其作为唯一治疗点的作用是复杂的,需要进一步探索.
- 目前针对Aβ聚合的治疗策略面临挑战,包括生物可用性差,非目标效应和有限的临床疗效.
研究的目的:
- 审查阿尔茨海默病中Aβ聚合的机制.
- 探索旨在抑制或调节Aβ聚合的各种治疗策略.
- 突出多功能和向治疗AD的重要性.
主要方法:
- 对有关阿尔茨海默氏症病原和治疗干预措施的现有文献的综述.
- 对基于结构的抑制剂,小分子,疗法和针对Aβ的免疫疗法的分析.
- 检查补充策略,包括金属合剂,β薄膜破碎剂,分子伴侣,定向疗法,抗炎剂和突触调制剂.
主要成果:
- Aβ聚合是AD病变发生的一个中心因素,但不是唯一的因素.
- 多种治疗方法,包括小分子,和免疫疗法,有前途,但面临重大障碍.
- 解决AD的多面性质需要探索Aβ以外的各种目标,例如tau和神经炎症.
结论:
- 有效的阿尔茨海默病治疗可能需要针对多种病理途径的多功能药物.
- 克服血脑屏障和改善药物输送对于治疗成功至关重要.
- 合理的药物设计和先进的输送系统对于开发下一代AD疗法至关重要.
更多相关视频
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...